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Abstract
Background—The Kenyan Ministry of Health initiated a voluntary medical male circumcision 
(VMMC) program in 2008. We used data from 2 nationally representative surveys to estimate 
trends in the number, demographic characteristics, and sexual behaviors of recently circumcised 
and uncircumcised HIV-uninfected men in Kenya.
Methods—We compared the proportion of circumcised men between the first and second Kenya 
AIDS Indicator Survey (KAIS 2007 and KAIS 2012) to assess the progress of Kenya’s VMMC 
program. We calculated the number of uncircumcised HIV-uninfected men. We conducted 
descriptive analyses and used multivariable methods to identify the variables independently 
associated with HIV-uninfected uncircumcised men aged 15–64 years in the VMMC priority 
region of Nyanza.
Results—The proportion of men who reported being circumcised increased significantly from 
85.0% in 2007 to 91.2% in 2012. The proportions of circumcised men increased in all regions, 
with the highest increases of 18.1 and 9.0 percentage points in the VMMC priority regions of 
Nyanza and Nairobi, respectively. Half (52.5%) of HIV-uninfected and uncircumcised men had 
never been married, and 84.6% were not using condoms at all times with their last sexual partner.
Conclusions—VMMC prevalence has increased across Kenya demonstrating the success of the 
national program. Despite this accomplishment, the Nyanza region remains below the target to 
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circumcise 80% of all eligible men aged 15–49 years between 2009 and 2013. As new cohorts of 
young men enter into adolescence, consistent focus is needed. To ensure sustainability of the 
VMMC program, financial resources and coordinated planning must continue.
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INTRODUCTION
In 2007, the first Kenya AIDS Indicator Survey (KAIS 2007) found that the national 
prevalence of HIV in Kenya was 7.1% among persons aged 15–64 years.1 KAIS 2007 also 
found that 85.0% of men in Kenya had been circumcised, and that the national prevalence of 
HIV infection in circumcised men was 3.9% [95% confidence interval (CI): 3.3 to 4.5] 
compared with 13.2% (95% CI: 10.8 to 15.7) in uncircumcised men.1 The highest 
prevalence of HIV (14.9%) and the lowest prevalence of male circumcision (46.4%) were 
both in Nyanza region.1
In November 2008, Kenya’s Ministry of Health began the implementation of an ambitious 
voluntary medical male circumcision (VMMC) program.2,3 The program was initiated after 
the results of 3 randomized controlled trials showed that male circumcision could reduce the 
risk of acquiring HIV infection among men by approximately 60%.4–6 The World Health 
Organization and Joint United Nations Programme on HIV/AIDS subsequently issued 
recommendations encouraging the use of VMMC as an effective HIV prevention 
intervention.7 Additionally, 1 modeling study showed that 5 HIV infections could be averted 
for every 36 men circumcised, saving up to 6200 US dollars per every HIV infection averted 
before 2025 in Kenya’s Nyanza region.8 Planning for the VMMC program in Kenya relied 
heavily on data from the 1999 census, the 2003 Kenya Demographic and Health Survey, and 
KAIS 2007, which showed that 15% of Kenyan men aged 15–64 years were 
uncircumcised.1,9,10 Circumcision prevalence varied by region, with Nyanza region having 
the lowest prevalence (46.4%) followed by Nairobi, Rift Valley, and Western regions.1 The 
number of HIV-uninfected men who were uncircumcised at the time of KAIS 2007 was 
estimated to be 1.2 million, and the Nyanza and Rift Valley regions were estimated to have 
the largest number of uncircumcised HIV-uninfected men (601,709 and 235,688, 
respectively). Together with Nairobi and Western regions, these 4 regions accounted for 
nearly 90% of all uncircumcised HIV-uninfected men in the country.1
Kenya set a strategic target to increase the percentage of circumcised men nationally from 
85% to 94% in 3–5 years by performing 860,000 VMMCs (80% of estimated need) in men 
aged 15–49 years by 2013. The brief duration was designed to maximize the public health 
impact11 and was planned to result in the reduction of the percentage of uncircumcised men 
from 15% to 9% nationally. Programmatic data indicated that 560,000 VMMCs had been 
completed in Kenya by the end of December 2012, bringing the national VMMC program 
achievement to within 65% of its strategic target. Moreover, 80% of these VMMCs were in 
the Nyanza region alone (Personal Communication, Kenya Ministry of Health, June 26, 
2013).
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Using data from the second Kenya AIDS Indicator Survey (KAIS 2012), we describe the 
progress that has been made in the Kenya VMMC program from 2007 to 2012. We further 
describe the current unmet need, including comparing the characteristics of the 
uncircumcised HIV-uninfected and the recently circumcised men in Kenya.
METHODS
Study Design
KAIS 2012 was a national population-based cross-sectional study, which sampled 
households across 9 programmatic regions of Kenya between October 2012 and February 
2013. Details of its methods have been described elsewhere.12 Because of regional 
insecurity, the North Eastern region was not included in the survey. A 2-stage cluster 
sampling design was used to derive estimates of the prevalence and sociodemographic, 
behavioral, and biological correlates of HIV infection that were representative at the 
regional level for the study’s adult and adolescent population (aged 15–64 years).
Study Population
All individuals aged 15–64 years, who were either usual residents or had stayed overnight in 
the household on the night before the survey, were eligible to participate. For this analysis, 
we have restricted our study population to men aged 15–64 years.
Measurements
Trained interviewers administered structured questionnaires that included sociodemographic 
characteristics and sexual behaviors. The questionnaire administered to men included items 
on knowledge of the benefits of male circumcision, intention to be circumcised, and for 
circumcisions that had occurred in last 3 years, where, when, and by whom the circumcision 
had been performed. To eliminate data entry time lag and ensure high standards of data 
quality, the survey used low-cost portable netbooks for data capture in the field (Mirus 
Innovations, Mississauga, Ontario, Canada). The netbooks allowed on-screen validations 
and data management quality checks, minimizing data transcription errors while 
simultaneously increasing data security and confidentiality.13 In addition, a blood sample 
was taken for biologic testing at the National HIV Reference Laboratory in Nairobi.
Laboratory Tests
As a service to study participants, respondents were given the opportunity to learn their HIV 
status within their homes through home-based testing and counseling using venous blood 
samples collected for the survey or a separate capillary sample. Methods for home-based 
testing and counseling were consistent with national guidelines for HIV testing.14 All 
specimens for centralized testing were transported from the field to the National HIV 
Reference Laboratory, where HIV tests were performed. Specimens were screened with 
Vironostika HIV-1/2 UNIF II Plus O Enzyme Immunoassay (BioMérieux, Marcy l’Etoile, 
France). Specimens testing negative by the screening assay were reported as a final result 
negative. Specimens testing positive by the screening assay were confirmed using the Murex 
HIV.1.2.O HIV Enzyme Immunoassay (DiaSorin SpA, Saluggia, Italy). Samples showing 
discordant results after confirmatory testing were tested again with the 2 assays. Polymerase 
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chain reaction (Cobas AmplicorHIV-1 Monitor Test, version 1.5; Roche Molecular 
Diagnostics, Pleasanton, CA) was performed to resolve specimens with twice-discordant 
results. All positive specimens and 5% of negative specimens were retested for quality 
assurance purposes using the same testing algorithm at the Kenya Medical Research 
Institute Laboratory.
Data Analysis
We compared the proportion of circumcised men between KAIS 2007 and KAIS 2012 to 
assess the progress of Kenya’s VMMC program. We also calculated the number of HIV-
uninfected men who had not been circumcised from estimates of the population and of the 
prevalence of circumcision and HIV infection in each region. National and regional numbers 
of circumcised, uncircumcised, and HIV-uninfected uncircumcised men were estimated 
based on the observed prevalence of circumcision and 2012 projected population estimates 
from the 2009 Kenyan Population and Household Census.15 Uncertainty bounds were 
calculated for the population estimates based on 95% confidence intervals (CI). Final 
population estimates presented were rounded to the nearest 1000 persons. We also 
conducted descriptive analyses to examine the demographic characteristics and risk and 
protective behaviors of recently circumcised and uncircumcised HIV-uninfected men. 
Finally, using multivariable logistic regression analysis, we calculated adjusted odds ratios 
(aOR) and 95% CI to identify variables independently associated with being HIV-uninfected 
and uncircumcised in the VMMC priority region of Nyanza. We selected variables with a P 
value of < 0.1 in bivariate analyses for final multivariable models and used backwards 
elimination, if they did not remain significant at a P value of < 0.05. We performed all 
analyses using the procedures for surveys in SAS software (version 9.3; SAS Institute Inc., 
Cary, NC). Analyses accounted for the stratified cluster design of the survey. Each response 
was weighted to account for its sampling probability and adjusted for survey nonresponse. 
As estimates based on small sample sizes are unreliable and are not likely to be nationally or 
regionally representative, we suppressed estimates based on denominators less than 25 
observations.
Ethical Considerations
We obtained verbal informed consent from all participants for both the interview and blood 
sample. The study was approved by the Kenya Medical Research Institute’s Ethical Review 
Committee, the Institutional Review Board of the US Centers for Disease Control and 
Prevention, and the Committee on Human Research of the University of California, San 
Francisco.
RESULTS
We identified 16,383 eligible adults in 9189 eligible households. Of these, 7452 (45.4%) 
were men; 5766 (77.3%) were interviewed, and 4836 (64.8%) provided blood specimens.
Overall, 91.2% of men (95% CI: 89.7 to 92.7; n = 5229) reported being circumcised, 8.8% 
(95% CI: 7.3 to 10.3; n = 509) reported being uncircumcised, 0.1% (n = 8) did not report 
their circumcision status, and 0.3% (n = 20) had missing data. The overall prevalence of 
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HIV infection in uncircumcised men was 16.9% (95% CI: 13.1 to 20.7) compared with 3.1% 
(95% CI: 2.5 to 3.8; P < 0.001) in circumcised men.
The proportion of men who reported being circumcised increased by 6.2% (95% CI: 5.1 to 
7.3; P < 0.001) from 85.0% (95% CI: 83.2 to 86.8) in KAIS 2007 to 91.2% (95% CI: 89.7 to 
92.7) in KAIS 2012 (Table 1). The proportion of circumcised men increased in all age 
groups, with the largest increase of 9.4% (95% CI: 7.2 to 11.6; P < 0.001) in men aged 15–
24 years and lowest increase of 1.9% (95% CI: −1.2 to 5.0; P = 0.541) in men aged 55–64 
years. Proportions of circumcised men increased from 2007 to 2012 in all regions, with 
highest increases of 18.1% (95% CI: 13.6 to 22.6; P < 0.001), 9.0% (95% CI: 5.9 to 12.1; P 
< 0.001), 4.1% (95% CI: 1.7 to 6.5; P = 0.001), and 5.1% (95% CI: 2.3 to 7.9; P < 0.001) in 
VMMC priority regions of Nyanza (from 48.2% to 66.3%), Nairobi (from 83.2% to 92.2%), 
Rift Valley (88.7%–92.8%), and Western regions (87.8%–92.9%), respectively. Increases in 
circumcision prevalence by age group were highest in the Nyanza region, where the 
proportion increased by 25.2% (95% CI: 18.2 to 32.2; P < 0.001) and 21.8% (95% CI: 12.4 
to 31.2; P < 0.001) in men aged 15–24 years and aged 25–34 years, respectively (Table 1). 
The biggest percentage increases in circumcision prevalence by ethnic groups were among 
men belonging to the Luo tribe (30.6%, 95% CI: 26.0 to 35.2; P < 0.001) and among men 
belonging to smaller tribes, for which individual tribal affiliation was not collected and were 
categorized as “Other” (25.9%, 95% CI: 20.5 to 31.3; P < 0.001). The Other category 
included Teso and the traditionally noncircumcising tribes who reside in the Turkana region.
Table 2 shows the estimated number of men aged 15–64 years in the 7 former provinces of 
Kenya by circumcision and HIV status. The percentage of HIV-uninfected men who were 
uncircumcised at the time of the survey was estimated to be 7.3% of the total population of 
men aged 15–64 years, which corresponded to 756,000 men. The priority regions of Nyanza, 
Rift Valley, and Nairobi continued to have the highest HIV prevalence among 
uncircumcised men aged 15–64 years [25.9% (95% CI: 20.5 to 31.3), 10.2% (95% CI: 2.7 to 
17.7), and 9.5% (95% CI: 2.3 to 16.7), respectively] and large estimated numbers of 
uncircumcised HIV-uninfected men (345,000, 180,000, and 85,000, respectively) (Table 2). 
These 3 regions account for 80.7% of all uncircumcised HIV-uninfected men in the country. 
The priority region of Western, however, had the lowest HIV prevalence at 4.2% (95% CI: 
0.0 to 10.7) and the lowest estimated number of uncircumcised HIV-uninfected men at 
73,000.
The majority (84.9%, 95% CI: 80.8 to 88.9) of HIV-uninfected men who were circumcised 
in the last 3 years were aged 15–24 years, and 28.0% (95% CI: 21.1 to 35.0) were from the 
Luo ethnic tribe (Table 3). More than half lived in Rift Valley (34.8%, 95% CI: 27.1 to 42.5) 
or Nyanza region (22.5%, 95% CI: 16.2 to 28.9), 68.2% (95% CI: 62.0 to 74.5) lived in rural 
areas, and 43.0% (95% CI: 35.8 to 50.1) had reported secondary education or higher 
education. The majority (86.8%, 95% CI: 82.9 to 90.7) had never married or cohabited, and 
52.2% (95% CI: 46.1 to 58.3) were not yet sexually active. Most (57.6%, 95% CI: 50.7 to 
64.4) reported ever having been tested for HIV, and over half (52.6%, 95% CI: 43.6 to 61.5) 
of those sexually active in the past 12 months used a condom with the last sexual partner.
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Among HIV-uninfected men who were uncircumcised, 51.4% (95% CI: 46.0 to 56.8) were 
aged 15–24 years and 52.5% (95% CI: 47.0% t 58.0%) had never married or cohabited 
(Table 3). The majority (61.2%, 95% CI: 53.9 to 68.5) were from the Luo ethnic tribe, and 
nearly half (46.7%, 95% CI: 39.2 to 54.3) lived in the Nyanza region. The majority of 
sexually active HIV-uninfected and uncircumcised men (84.6%, 95% CI: 79.8 to 89.5) were 
not using condoms at all times with their last sexual partner in the past 12 months, and 
40.4% (95% CI: 34.2 to 46.7) reported never having been tested for HIV. The majority 
(72.1%, 95% CI: 66.1 to 78.1), however, knew circumcision protected men somewhat from 
HIV, and over half (53.0%, 95% CI: 46.7 to 59.2) reported that they intended to be 
circumcised in the future. Intention to be circumcised was highest among young men aged 
15–24 years (69.6%, 95% CI: 61.7 to 77.4) and men who had never married or cohabited 
(73.6%, 95% CI: 66.1 to 81.1) (data not shown).
In Nyanza region, of the 772 men we surveyed, 13.4% (95% CI: 8.7 to 18.2) (n = 104) were 
HIV-uninfected and recently circumcised (past 3 years), and 26.3% (95% CI: 18.9 to 33.7) 
(n = 198) were HIV-uninfected and uncircumcised (data not shown). Over half (51.8%, 95% 
CI: 41.2 to 62.3) of men aged 15–24 years compared with 93.9% (95% CI: 87.6 to 100.0) of 
men aged 45–64 years were HIV-uninfected and uncircumcised (Table 4). Seventy-five 
percent (75.8%, 95% CI: 67.1 to 84.4) of men with secondary or higher level of education 
were HIV-uninfected and uncircumcised compared with 59.1% (95% CI: 50.1 to 68.1) of 
men who had completed primary level education. A higher proportion of men who were 
married or cohabiting (80.5%, 95% CI: 72.3 to 88.8) were HIV-uninfected and 
uncircumcised compared with men who had never married or cohabited (46.6%, 95% CI: 
36.0 to 57.2). Overall, 81.9% (95% CI: 74.1 to 90.0) of men who did not use a condom 
consistently with the last sex partner in the past 12 months compared with 50.5% (95% CI: 
36.4 to 64.5) of men who did were HIV-uninfected and uncircumcised. Moreover, 74.3% of 
men who reported 4 or more lifetime number of sex partners compared with 42.0% (95% 
CI: 21.3 to 62.7) of men who reported no partners were HIV-uninfected and uncircumcised.
In multivariable logistic regression, being younger [aged 15–24 years (aOR: 0.12, 95% CI: 
0.03 to 0.55) and 25–34 years (aOR: 0.13, 95% CI: 0.03 to 0.57)] was significantly 
associated with lower odds of being HIV-uninfected and uncircumcised compared with men 
aged 45–64 years. In addition, men who reported condom use with the last sexual partner in 
the past 12 months had significantly lower odds of being HIV-uninfected and uncircumcised 
(aOR: 0.31, 95% CI: 0.16 to 0.60).
DISCUSSION
We found a significant increase in the proportion of men aged 15–64 years who reported 
being circumcised from 2007 to 2012. The highest increase in VMMCs was observed in 
regions and subpopulations where Kenya’s National VMMC program has targeted since 
2008, including Nyanza region, men from the Luo tribe, and men aged 15–44 years. The 
gains made in VMMC coverage over the past 5 years can be attributable to adoption of 
focused strategies for scaling up VMMC.
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Kenya’s minimum VMMC package includes provider-recommended and offered HIV 
testing and counseling, risk-reduction counseling and behavior change communication, 
sexually transmitted infection screening and treatment, condom promotion and provision, 
and medical circumcision surgery as per World Health Organization guidelines. 
Circumcised men are also advised to abstain from sex for 6 weeks after circumcision to 
allow for healing and to use condoms when sexual behavior resumes.11 The vast majority of 
recently circumcised men reported ever having been tested for HIV. Almost half of the HIV-
uninfected men who were recently circumcised reported consistently using condoms, and 
over half reported using a condom at last sex, suggesting that risk compensation is not as 
widespread as was originally feared, and that many of those who were recently circumcised 
are heeding the prevention messages included in the complete package of circumcision 
services.16
Conversely, HIV-uninfected uncircumcised men are still engaging in risky behaviors, with 
only 21% reporting that a condom was used with the last sexual partner in the past 12 
months. However, the difference in condom use between those recently circumcised 
compared with uncircumcised HIV-uninfected men may also be because of the factors 
unrelated to exposure to prevention messages in the minimum package. Recently 
circumcised men may be more disposed to prevention approaches overall, leading to an 
increase in uptake of both circumcision and condom use. It is also possible that many of the 
uncircumcised men are older and in monogamous married relationships and therefore feel 
no need to adhere to either prevention intervention.
It is critical that Kenya’s VMMC program remains robust and explores approaches to 
promote and encourage HIV-uninfected uncircumcised men to access VMMC, offered as 
part of a comprehensive HIV prevention package, which allows access to other prevention 
benefits, including risk-reduction counseling, HIV testing, and condom use. Targeted 
strategies are needed for those men in Nyanza region who are HIV-uninfected and 
uncircumcised, the majority of whom are aged 15–24 years, report first sex between the ages 
of 15–19 years, live in rural areas, have never married or cohabited, and have previously 
been tested for HIV infection. A positive finding is that more than half of all uncircumcised 
men stated an intention to be circumcised. This finding was strongest among young men 
aged 15–24 years and men who had never been married or cohabited.
We recognize the limitations of our study, including the fact that comparison of the KAIS 
2007 and KAIS 2012 data must be done with caution because the sampling frameworks of 
the 2 surveys were slightly different. North Eastern region was not included in KAIS 2012 
and had high rates of circumcision in KAIS 2007, so overall prevalence of circumcision in 
KAIS 2012 is potentially underestimated. Circumcision status, condom use, and sexual 
behavior were measured through participants’ self-report, and, therefore, responses may 
have been biased toward socially desirable answers. Some noncircumcising tribes, for 
example, Turkana and Teso, were combined with other smaller tribes and could not be 
analyzed separately. Additionally, sample sizes were small for some subgroups and resulted 
in reduced precision in the estimates presented. Finally, because of the cross-sectional study 
design, the directionality of associations cannot be established.
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Notwithstanding these limitations, our study presents nationally representative population-
based data on VMMC that demonstrated substantial progress toward bringing an evidence-
based biomedical intervention to scale within a short period. The success of the Kenyan 
VMMC program should encourage other countries that are at various stages of scaling up 
VMMC to continue implementing VMMC actively for HIV prevention. For example, the 
success of Kenya’s 2009, 2010, and 2011 Rapid Results Initiative informed the Swaziland 
Male Circumcision Task Force’s decisions to adopt surgical, nonsurgical, and human 
resource efficiencies in scaling up VMMC.17 Overall, KAIS 2012 data show increased 
uptake of VMMC across Kenya, demonstrating the success of the national VMMC program. 
Despite this accomplishment, the Nyanza region remains below the target to circumcise 80% 
of all eligible men aged 15–49 years between 2009 and 2013, with the aim of averting an 
estimated 900,000 HIV infections over 20 years.11 Moreover, KAIS 2012 found that men 
with the highest HIV prevalence were aged 45–49 years.18 Therefore, strategies are needed 
to continue targeted messaging about the benefits of VMMC is needed, especially in Nyanza 
region and among older men.
Furthermore, as new cohorts of young men enter into adulthood, they will also require 
consistent targeting. Finally, as part of the long-term strategy of the national VMMC 
program, implementation and scale-up of infant circumcision services, integrated into 
routine maternal and child health services, is expected to maximize the long-term public 
health impact of VMMC on the HIV epidemic.2 To ensure sustainability of the VMMC 
program, continued financial resources and coordinated planning are necessary.
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